双相情感障碍市场规模、份额、成长分析，按类型、按药物类别、按分销管道、按地区 - 行业预测，2025 年至 2032 年

2023 年全球双极性情感障碍市场规模价值53.6 亿美元，预计将从2024 年的54.9 亿美元成长到2032 年的66.4 亿美元，预计在预测期内（2025-2032 年）的复合年增长率为1.2 %。

忧郁症，现称为双极性情感障碍，其特征是情绪波动剧烈，包括躁症和忧郁症发作。遗传易感性在疾病中起着重要作用，涉及多个基因而不是单一的致病因素。双极性情感障碍主要有三种：双极 I 型、双相 II 型和週期性障碍。有趣的是，印度人一生中罹患躁郁症的风险仅为 0.1%，而美国则高得多，达到 4.4%。由于宣传活动的不断加强、精准情绪评估技术的进步以及发病率的上升，双相情感障碍治疗市场正在不断扩大。此外，由于副作用，三环抗忧郁药物的使用正在减少，从而转向更有效的治疗选择。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和资料资料
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管格局
• 案例研究
• 客户和购买标准分析

双极性情感障碍市场规模（按类型）

• 市场概况
• 情绪稳定剂
• 抗惊厥药
• 抗精神病药物
• 抗忧郁症
• 抗焦虑药物
• 其他类型

双极性情感障碍市场规模（依药物类别）

• 市场概况
• 选择性血清素再回收抑制剂
• 血清素正肾上腺素再回收抑制剂
• 三环抗忧郁药物
• 单胺氧化酵素抑制剂
• 苯二氮平类
• β受体阻断剂
• 其他药物类别

双极性情感障碍市场规模（按分销管道）

• 市场概况
• 医院药房
• 零售药局
• 网路药局

双极性情感障碍市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较（2022-2024 年）

主要企业简介

• Eli Lilly and Company（USA）
• GlaxoSmithKline plc（UK）
• Pfizer Inc.（USA）
• AstraZeneca plc（UK）
• Otsuka Holdings Co., Ltd.（Japan）
• H. Lundbeck A/S（Denmark）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Takeda Pharmaceutical Company Limited（Japan）
• AbbVie Inc.（USA）
• Novartis International AG（Switzerland）
• Merck & Co., Inc.（USA）
• Bristol Myers Squibb Company（USA）
• Alkermes plc（Ireland）
• Mylan NV（USA）
• Neurocrine Biosciences, Inc.（USA）
• Vanda Pharmaceuticals Inc.（USA）
• Sunovion Pharmaceuticals Inc.（USA）
• Intra-Cellular Therapies, Inc.（USA）
• Acadia Pharmaceuticals Inc.（USA）
• Reviva Pharmaceuticals Holdings, Inc.（USA）

结论和建议

Global Bipolar Disorder Market size was valued at USD 5.36 billion in 2023 and is poised to grow from USD 5.49 billion in 2024 to USD 6.64 billion by 2032, growing at a CAGR of 2.4% during the forecast period (2025-2032).

Manic depression, now known as bipolar disorder, is characterized by extreme mood fluctuations, including manic and depressive episodes. Genetic predisposition plays a significant role in this condition, with multiple genes involved rather than a single causative factor. There are three main types of bipolar disorder: bipolar I, bipolar II, and cyclothymic disorder. Interestingly, while India's lifetime risk for bipolar disorder is just 0.1%, the United States has a significantly higher prevalence at 4.4%. The market for bipolar disorder treatment is expanding, driven by increasing awareness campaigns, advancements in technology for accurate mood assessment, and the rising incidence of the disorder. Additionally, the use of tricyclic antidepressants is declining due to their side effects, leading to a shift toward more effective treatment options.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Bipolar Disorder market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Bipolar Disorder Market Segmental Analysis

Global Bipolar Disorder Market is segmented by Type, Drug Class, Distribution Channel and region. Based on Type, the market is segmented into Mood stabilizer, Anticonvulsants, Antipsychotic drugs, Antidepressant drugs, Antianxiety drugs and Other Types. Based on Drug Class, the market is segmented into Selective serotonin reuptake inhibitor, Serotonin norepinephrine reuptake inhibitor, Tricyclic antidepressant drugs, Monoamine oxidase inhibitors, Benzodiazepines, Beta blockers and Other Drug Classes. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Bipolar Disorder Market

The global bipolar disorder market is expected to witness significant growth driven by a strong focus on enhancing product offerings and an increasing prevalence of mental health issues. Key players in the industry are actively expanding their product portfolios, which includes the introduction and approval of new pharmaceuticals specifically targeting bipolar disorder. For instance, the FDA recently approved Allergan plc and Gedeon Richter plc's supplemental new drug application for VRAYLAR (cariprazine), underscoring the commitment to advancing treatment options. Furthermore, rising awareness initiatives and government efforts aimed at highlighting the impacts of bipolar disorder, alongside a growing demand for effective antidepressants, are contributing to a reduction in the overall burden of this mental health condition.

Restraints in the Global Bipolar Disorder Market

The Global Bipolar Disorder market faces significant challenges due to several restraints that could impede its growth. A prominent issue is the insufficient availability of effective medications and suitable treatment protocols, which complicates management of the condition. Additionally, the expiration of patents for major drugs, such as Latuda, Abilify Maintena, and Risperdal Consta, poses further limitations, potentially leading to increased competition from generic alternatives like lithium. Moreover, the absence of reliable diagnostic methods and the adverse side effects associated with existing treatments exacerbate these market constraints. However, advancements in drug combination therapies present potential avenues for future growth within this sector.

Market Trends of the Global Bipolar Disorder Market

The global bipolar disorder market is witnessing significant growth, driven by the rising prevalence of mental health disorders, particularly among children and adolescents. Increased awareness and reduced stigma surrounding mental illnesses have led to higher diagnosis rates of bipolar disorder, prompting a surge in demand for effective treatment options. Advances in pharmacotherapy and psychotherapy, combined with the integration of digital health solutions, are further transforming the therapeutic landscape. Additionally, greater emphasis on personalized medicine and early intervention strategies is anticipated to enhance patient outcomes, solidifying bipolar disorder as a critical area within the broader mental health market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Customer & Buying Criteria Analysis

Global Bipolar Disorder Market Size by Type & CAGR (2025-2032)

• Market Overview
• Mood stabilizer
• Anticonvulsants
• Antipsychotic drugs
• Antidepressant drugs
• Antianxiety drugs
• Other Types

Global Bipolar Disorder Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Selective serotonin reuptake inhibitor
• Serotonin norepinephrine reuptake inhibitor
• Tricyclic antidepressant drugs
• Monoamine oxidase inhibitors
• Benzodiazepines
• Beta blockers
• Other Drug Classes

Global Bipolar Disorder Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Bipolar Disorder Market Size & CAGR (2025-2032)

• North America (Type, Drug Class, Distribution Channel)
  • US
  • Canada
• Europe (Type, Drug Class, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Drug Class, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Drug Class, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Drug Class, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Holdings Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H. Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alkermes plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurocrine Biosciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vanda Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sunovion Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intra-Cellular Therapies, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acadia Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Reviva Pharmaceuticals Holdings, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations